Ibex Wealth Advisors Gilead Sciences, Inc. Transaction History

Ibex Wealth Advisors

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	SELL	$63.15 - $72.88 $4.13 Million - $4.77 Million	-65,433 Reduced 99.95%	35 $2,000
Q1 2024 Apr 18, 2024	BUY	$71.58 - $87.29 $4.68 Million - $5.71 Million	65,405 Added 103817.46%	65,468 $5.62 Million
Q4 2023 Jan 29, 2024	SELL	$73.27 - $83.09 $4.55 Million - $5.16 Million	-62,149 Reduced 99.9%	63 $5.09 Million
Q3 2023 Nov 07, 2023	SELL	$73.94 - $80.67 $342,785 - $373,986	-4,636 Reduced 6.94%	62,212 $4.66 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $106,687 - $121,550	1,380 Added 2.11%	66,848 $5.55 Million
Q4 2022 Feb 06, 2023	BUY	$62.32 - $89.47 $27,296 - $39,187	438 Added 0.67%	65,468 $5.62 Million
Q3 2022 Oct 31, 2022	SELL	$59.54 - $68.01 $8,276 - $9,453	-139 Reduced 0.21%	65,030 $4.01 Million
Q2 2022 Aug 16, 2022	BUY	$57.72 - $65.01 $3.12 Million - $3.51 Million	54,048 Added 486.0%	65,169 $4.03 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $644,128 - $807,162	11,121 New	11,121 $661,000
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $1.93 Million - $2.24 Million	-26,726 Closed	0 $0
Q1 2020 May 05, 2020	BUY	$62.63 - $80.22 $1.67 Million - $2.14 Million	26,726 New	26,726 $2 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Ibex Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on Ibex Wealth Advisors with notifications on news.